TCM
IBRX icon

Traynor Capital Management’s ImmunityBio IBRX Stock Holding History

Traynor Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,500
Closed -$16.6K – 282
2024
Q4 		$16.6K Sell
6,500
-9,900
-60% -$41.2K ﹤0.01% 282
2024
Q3 		$61K Buy
16,400
+6,800
+71% +$31.5K ﹤0.01% 256
2024
Q2 		$60.7K Buy
9,600
+5,600
+140% +$36.9K ﹤0.01% 251
2024
Q1 		$21.5K Buy
4,000
+1,000
+33% +$4.53K ﹤0.01% 266
2023
Q4 		$15.1K Buy
+3,000
New +$9.41K ﹤0.01% 237

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Traynor Capital Management's IBRX Position: Q3 2025 in Review

Traynor Capital Management sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 18,610 shares — an estimated $47.8K sold.

Traynor Capital Management first reported a position in IBRX in Q3 2023 and held it in 8 quarters. The position peaked at $194K in Q2 2024. 262 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

  • Traynor Capital Management reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
  • Traynor Capital Management sold 18,610 ImmunityBio shares in Q3 2025, an estimated $47.8K.
  • Traynor Capital Management first reported a position in ImmunityBio in Q3 2023 and held it in 8 quarters.
  • Traynor Capital Management's ImmunityBio position peaked at $194K in Q2 2024.
  • 262 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Traynor Capital Management's 13F filing for Q3 2025, filed 3 Nov 2025.